T. M. Blicher

Benefit of Clopidogrel Therapy in Patients With Myocardial Infarction and Chronic Kidney Disease—A Danish Nation‐Wide Cohort Study

M. Madsen, J. Olesen, C. Torp-Pedersen, 2014, Journal of the American Heart Association.

Drug treatments for obesity

N. Bjarnason, T. M. Blicher, 2007, The Lancet.

Less use of standard guideline-based treatment of myocardial infarction in patients with chronic kidney disease: a Danish nation-wide cohort study.

C. Torp‐Pedersen, M. Madsen, J. Olesen, 2013, European heart journal.

Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial

J. Rosenstock, M. Davies, H. Watada, 2019, JAMA.

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.

S. Heller, R. Pratley, J. Eriksson, 2019, The lancet. Diabetes & endocrinology.

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes

T. Bækdal, M. Thomsen, G. Golor, 2019, Clinical Pharmacokinetics.

Introducing an adverse drug event manager

E. Jimenez‐Solem, J. Kampmann, H. R. Christensen, 2013 .